Angelique Kany Kany Luabeya

Author

Also Known As

A Luabeya, A. K. K. Luabeya, A. Kany Kany Luabeya, A. Luabeya, A.K.K. Luabeya, Angelique K.K. Luabeya, Angelique Kany Kany Luabeya, Angelique K Luabeya, Angelique K. K. Luabeya, Angelique K. Luabeya

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University of Cape Town South African Tuberculosis Vaccine Initiative South African Medical Research Council Stellenbosch University Aeras

About

Angelique Kany Kany Luabeya is an author at University of Cape Town specializing in medicine, tuberculosis, and vaccination.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	885
2	Immunology	7	7	729
3	Epidemiology	3	3	83
4	Public Health	2	2	65
5	Medical Laboratory Science	1	1	100

Angelique Kany Kany Luabeya

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, New England Journal of Medicine	2021	652
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults Angelique Kany Kany Luabeya, Benjamin M. Kagina, Michèle Tameris, Vaccine VaccinationPulmonary TuberculosisTuberculosis PreventionImmunologyMycobacterium Tuberculosis	2015	190
Optimization and Interpretation of Serial QuantiFERON Testing to Measure Acquisition of <i>Mycobacterium tuberculosis</i> Infection Elisa Nemes, Virginie Rozot, Hennie Geldenhuys, American Journal of Respiratory and Critical Care Medicine	2017	159
Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial Adam Penn‐Nicholson, Michèle Tameris, Erica Smit, The Lancet Respiratory Medicine VaccinationVaccine SafetyPulmonary TuberculosisTuberculosis PreventionImmunology	2018	146
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial Thomas J. Scriba, Andrew Fioré-Gartland, Adam Penn‐Nicholson, The Lancet Infectious Diseases	2021	141
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting Adam Penn‐Nicholson, Hennie Geldenhuys, Wivine Burny, Vaccine	2015	137
Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial Michèle Tameris, Helen Mearns, Adam Penn‐Nicholson, The Lancet Respiratory Medicine VaccinationVaccine SafetyPulmonary TuberculosisTuberculosis PreventionImmunology	2019	134
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, American Journal of Respiratory and Critical Care Medicine	2018	112
The Candidate TB Vaccine, MVA85A, Induces Highly Durable Th1 Responses Michèle Tameris, Hennie Geldenhuys, Angelique Kany Kany Luabeya, PLoS ONE	2014	100
Noninvasive Detection of Tuberculosis by Oral Swab Analysis Angelique Kany Kany Luabeya, Rachel C. Wood, Justin Shenje, Journal of Clinical Microbiology Human AirwaysViscous MaterialPulmonary TuberculosisMedicineTuberculosis Prevention	2018	100

Page 1